The Seattle biotech Omeros (OMER) has reported sharply lower sales of its cataract surgery drug in the fourth quarter after losing favorable Medicare reimbursement at the end of last year.
Lacking a reimbursement fix, Omeros offered a bleak sales outlook for this year for the drug, Omidria, raising the risk that the company might end up in default on a business loan.
About the Author Reprints
